Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.

Lederman, R J; Tenaglia, A N; Anderson, R D; Hermiller, J B; Rocha-Singh, K; Mendelsohn, F O; Hiatt, W R; Moon, T; Whitehouse, M J; Annex, B H

Lederman, R J; Tenaglia, A N; Anderson, R D; Hermiller, J B; Rocha-Singh, K; Mendelsohn, F O; Hiatt, W R; Moon, T; Whitehouse, M J; Annex, B H.

Afiliação

Lederman RJ; Department of Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.

Am J Cardiol ; 88(2): 192-5, A6-7, 2001 Jul 15.

Article em En | MEDLINE | ID: mdl-11448424

ABSTRACT

ABSTRACT

The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.

Assuntos

Fator 2 de Crescimento de Fibroblastos/uso terapêutico; Claudicação Intermitente/tratamento farmacológico; Neovascularização Fisiológica/efeitos dos fármacos; Método Duplo-Cego; Humanos; Proteínas Recombinantes/uso terapêutico; Projetos de Pesquisa

Buscar no Google

Imprimir

XML

PubMed Links

Base de dados: MEDLINE Assunto principal: Fator 2 de Crescimento de Fibroblastos / Neovascularização Fisiológica / Claudicação Intermitente Idioma: En Ano de publicação: 2001 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links